Clinical trials: Diabetic Macular Oedema
Diabetic Macular Oedema
Intravitreal Macugen for Ischaemic Diabetic Macular Oedema
Diabetic macular oedema (DME) is one of the leading causes of blindness in the United Kingdom's working population. It affects the macula, which lies at the centre of the retina, at the back of the eye.
- Trial name
- MIDME (NCT01175070)
- Testing
- Intravitreal injection of pegaptanib sodium
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- University of Oxford
Diabetic Macula Edema
Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
The purpose of this study is to evaluate the efficacy and safety of brolucizumab in treatment of patients with visual impairment due to diabetic macular edema (DME).
- Trial name
- BUZZARD (NCT04079231)
- Testing
- Brolucizumab, Aflibercept
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema
Combined Intravitreal Bevacizumab With Topical Timolol-Dorzolamide Eye Drops in Diabetic Macular Edema
This study is a double-blind randomized clinical trial in Diabetic patients (type 2) over 18 years of age who have diabetic macular edema with involvement of the central 1 millimeter (central macular thickness is more than 300…
- Trial name
- NCT05083689
- Testing
- Injections of 1.25 mg of intravitreal bevacizumab with Timolol and Dorzolamide, Injections of 1.25 mg of intravitreal bevacizumab with artificial tears
- Where
- Iran
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Shahid Beheshti University of Medical Sciences
Diabetic Macular Edema
Efficacy and Safety of 9MW0813 in Subjects With Diabetic Macular Edema
Phase III clinical study of the efficacy and safety of 9MW0813 and aflibercept (EYLEA®) in patients with diabetic macular edema (DME) in a multicenter, randomized, double-blind, parallel active-controlled study.
- Trial name
- NCT05324774
- Testing
- 9MW0813, Aflibercept
- Where
- China
- Volunteers
- 346 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Diabetic Macular Edema
Intravitreal Aflibercept InjectiOn in Vitrectomized Eyes for Treatment of Diabetic Macular Edema
This a non-interventional retrospective study on the efficiency and the tolerance of intravitreal injections of Aflibercept on vitrectomized eyes in the diabetic macular oedema
- Trial name
- MODEVA (NCT02874859)
- Where
- 8 sites in France
- Volunteers
- 49 people
- Sponsor
- Lille Catholic University
Diabetic Macular Edema (DME)
A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial to Evaluate the Safety, Efficacy, and Durability of a Single Intravitreal Injection of 4D-150 versus Aflibercept in Adults with Diabetic Macular Edema (4SIGHT)
- Trial name
- 4SIGHT (NCT07867080)
- Testing
- 4D-150 IVT (3x10^10 vg), EYELEA ® (aflibercept) Injection 2 mg (0.05mL)
- Where
- 87 sites in United States, China and 1 more
- Volunteers
- 514 people
- Sponsor
- 4D Molecular Therapeutics
Diabetic Macular Edema
iOCT for Patients With Diabetic Macular Edema
Patients will be examined before and after surgery with a stand-alone OCT and intraoperative microscope integrated OCT
- Trial name
- NCT03328715
- Testing
- intraoperative OCT, stand-alone OCT
- Where
- Austria
- Volunteers
- 48 people
- Sponsor
- Vienna Institute for Research in Ocular Surgery
AMD - Age-Related Macular Degeneration, Diabetic Macular Edema
NOTAL-OCT V.2.5 vs Commercial OCT in AMD Patients
Primary objective: To evaluate the level of agreement between the NOTAL-OCT V2.5 and a commercial OCT in the presence of fluid as identified in the OCT images, in the central 10 degrees of the macula in AMD (Age-related Macular…
- Trial name
- NCT03969303
- Testing
- Notal Vision Optical Coherence Tomography Device Version 2.5 (NOTAL-OCT V2.5)
- Where
- United States
- Volunteers
- 287 people
- Sponsor
- Notal Vision Ltd.
Diabetic Macular Edema, Branch Retinal Vein Occlusion
Non-damaging Retinal Laser Therapy With PASCAL Laser for Macular Diseases
This trial seeks to prove the safety and efficacy of photothermal stimulation treatment to diabetic macular edema, chronic central serous retinopathy, macular edema secondary to branch retinal vein occlusion and macular…
- Conditions
- Diabetic Macular Edema, Branch Retinal Vein Occlusion, Chronic Central Serous Retinopathy, Macular Telangiectasia
- Trial name
- EPM (NCT01975103)
- Testing
- Topcon Endpoint Management
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Federal University of Rio Grande do Sul
Diabetes Mellitus, With Complications
New Concepts in Diabetic Macular Edema (DME)
Intravitreal ranibizumab injection procedure is simple and effective. In management of chronic DME there is no clear anatomical endpoint. Visual stability is the primary aim.
- Trial name
- DME (NCT04186702)
- Testing
- INTRAVITREAL RANIBIZUMAB INJECTION
- Volunteers
- 150 people
- Sponsor
- Ain Shams University
Diabetic Macular Edema
Laser vs Bevacizumab Injection Alone in Treatment of Diabetic Macular Edema
Currently, diabetic macular edema is treated is through injection of a medications such as off-label bevacizumab, which decreases the swelling in the retina.
- Trial name
- NCT02229175
- Testing
- bevacizumab, PASCAL Endpoint Management (EpM) laser treatment
- Where
- United States
- Sponsor
- University of California, San Francisco
Diabetic Retinopathy, Diabetic Macular Edema
PROTECT2: Diabetes Care - Eye Exam
The PROTECT2 pilot study is a single cohort prospective study to gather pilot data and finalize operational details of the main study.
- Trial name
- NCT03094819
- Testing
- Financial Incentive, Retinal Care DR
- Where
- United States
- Volunteers
- 4,500 people
- Sponsor
- Retinal Care Inc.
Diabetic Macular Edema
Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema
To evaluate the safety of intravitreal ranibizumab repeated injections in patients with diabetic macular edema regarding maintenance of retinal ganglion cell function.
- Trial name
- NCT02055911
- Testing
- Ranibizumab
- Where
- Brazil
- Sponsor
- Federal University of São Paulo
Diabetic Retinopathy
Sirolimus to Treat Diabetic Macular Edema
Objective: Diabetic macular edema (DME) is a frequent manifestation of diabetic retinopathy, a leading cause of blindness in the United States. The only proven treatment for DME is laser photocoagulation.
- Trial name
- SDME (NCT00711490)
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Eye Institute (NEI)
Diabetic Macular Edema
Randomized Clinical Trial of Intravitreal Bevacizumab Versus Intravitreal Bevacizumab Combined With Losartan in the Treatment of Diabetic Macular Edema
The aim of this study is to determine whether oral losartan is effective in the treatment of diabetic macular edema (DME) as an adjuvant for intravitreal bevacizumab (IVB).
- Trial name
- NCT02663141
- Testing
- Losartan, Intravitreal bevacizumab
- Where
- Iran
- Volunteers
- 57 people
- Sponsor
- Tehran University of Medical Sciences
Proliferative Diabetic Retinopathy, Macular Edema
Morphological and Functional Retinal Changes Following Retinal Photocoagulation
Imaging of retinal morphological changes with time secondary to laser treatment as assessed with high definition optical coherence tomography (OCT).
- Trial name
- pascal (NCT00682240)
- Testing
- laser treatment with PASCAL®, laser treatment with conventional laser system
- Where
- Austria
- Volunteers
- 64 people
- Sponsor
- Medical University of Vienna
Diabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD)
Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections
This Phase 4, multicenter, randomized, double-masked clinical study evaluates the efficacy and safety of chloroprocaine hydrochloride ophthalmic gel 3% (IHEEZO) compared with routine anesthesia (topical proparacaine 0.5% combined…
- Conditions
- Diabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion, Diabetic Retinopathy (DR)
- Trial name
- Quell (NCT07456826)
- Testing
- Chloroprocaine Ophthalmic Gel 3% (IHEEZO), Proparacaine Hydrochloride Ophthalmic Solution 0.5%, Lidocaine Hydrochloride Injection 2%
- Where
- United States
- Volunteers
- 236 people
- Sponsor
- Harrow Inc
Diabetic Macular Edema
Phase 2 Randomized Clinical Trial of Luminate® as Compared to Avastin® in the Treatment of Diabetic Macular Edema
A Phase 2 Multi center, Randomized, Controlled, Double-Masked Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of Luminate® (Alg-1001) As Compared To Avastin® In The Treatment Of Diabetic Macular Edema
- Trial name
- NCT02348918
- Testing
- Luminate 1.0mg, Luminate 2.0mg, Luminate 3.0mg
- Where
- 17 sites in United States
- Volunteers
- 218 people
- Sponsor
- Allegro Ophthalmics, LLC
Diabetic Macular Edema
Evaluation of RC28-E Injection in Diabetic Macular Edema
This is a non-randomized, open-label, multicenter, 48-week study to investigate the efficacy, safety and pharmacokinetics of RC28-E injection in the treatment of patients with diabetic macular edema.
- Trial name
- NCT04782115
- Testing
- intravitreal injection of RC28-E, Conbercept
- Where
- 37 sites in China
- Volunteers
- 156 people
- Sponsor
- RemeGen Co., Ltd.
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)
The FaReal study aims to evaluate the effectiveness, safety, clinical insights and treatment patterns in patients treated with faricimab, in neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) in…
- Trial name
- NCT06680817
- Testing
- Faricimab
- Where
- 59 sites in Austria, Bulgaria and 13 more
- Volunteers
- 875 people
- Sponsor
- Hoffmann-La Roche